PharmaEssentia (6446) investor relations material

Executive summary

• Q2 2026 revenue reached NT$6.86 billion, marking a 90% year-over-year increase, with monthly revenue exceeding NT$2 billion for three consecutive months.

• Net operating income for Q2 2026 was NT$3.16 billion, up 188% YoY, and net income was NT$2.53 billion, up 204% YoY.

• H1 2026 revenue grew 75% YoY to NT$11.98 billion, with net income for H1 at NT$4.68 billion, up 123% YoY.

• Completed the acquisition of Forus Therapeutics Inc. in June 2026, expanding the group's biopharmaceutical portfolio.

• Ongoing international arbitration with AOP Orphan Pharmaceuticals GmbH resulted in partial awards, with financial impacts and further legal actions pending.

Financial highlights

• Operating revenue for H1 2026 was NTD 11,976,809 thousand, up 75% year-over-year.

• Net income for H1 2026 reached NTD 4,679,591 thousand, more than double the prior year.

• Basic EPS for Q2 2026 was NT$6.13, up 202% YoY; H1 2026 EPS was NTD 11.35, compared to NTD 5.11 in H1 2025.

• Gross margin improved to 94.2% in Q2 2026 (up 6.7pp YoY) and 92% for H1 2026 (up from 88% in H1 2025).

• Cash and cash equivalents increased to NTD 24,470,683 thousand as of June 30, 2026.

Outlook and guidance

• Continued global expansion of ROPEG (Ropeginterferon alfa-2b) with regulatory approvals in Canada, and anticipated approvals in Japan and the U.S. for ET indication in August 2026.

• Early-stage pipeline in oncology and immunology expected to drive future growth, with four products targeted to enter Phase 1 clinical trials by 2027.

• Strategic focus on expanding PEG platform applications and broadening ROPEG’s therapeutic use in hematologic and solid tumor indications.

• Management continues to invest in R&D and global clinical trials to support future growth.

• Ongoing legal proceedings and arbitration outcomes may impact future financial results.